Abstracts tagged "autoimmune diseases"

Abstract Number: 1008 • ACR Convergence 2024
Immune Responses to Infection and Autoimmune Diseases in the UK Biobank
Choa Yun¹, May A. Beydoun², Lenore Launer² and Minkyo Song³, ¹National Institute on Aging, Rockville, MD, ²National Institute on Aging, Baltimore, MD, ³National Institutes on Aging, Baltimore, MD
Background/Purpose: Infections have been implicated as potential triggers for autoimmune responses, but studies primarily focused on the history of infection linked with autoimmune diseases. Large-scale…
Abstract Number: 1225 • ACR Convergence 2024
Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions
Qi Wang¹, Pratibha Chaudhary², Yu Chang³ and Megha Garg⁴, ¹Unity Hospital/Rochester Regional Health, Rochester, NY, ²Rochester General Hospital, Rochester, NY, ³National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁴Rochester Regional Health, Rochester, NY
Background/Purpose: Fibromyalgia is a non-autoimmune disease with widespread pain, severe fatigue, and sleep problems. There are limited studies examining the association between fibromyalgia and autoimmune…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1650 • ACR Convergence 2024
IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
Andre Limnander¹, Eva Conde¹, Seblewongel Asrat², Andrea Vecchione², Kaitlyn Gayvert², Paulina Pedraza², Carley Tasker², Sharon Huang², Dmitry Yarilin², Dylan Birchard², Li-Hong Ben², Wei Keat Lim², Andrew Murphy², Matthew Sleeman² and Jamie orengo¹, ¹Regeneron Pharmaceuticals, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: IL-33 is a pro-inflammatory cytokine that plays a role in asthma, COPD and autoimmune diseases. The role of IL-33 on B cell maturation and…
Abstract Number: 1764 • ACR Convergence 2024
Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus
Tatiana Borja¹, Bharati Matta², Lydia Thomas³, Jenna Battaglia⁴, Amanda Huang⁵, Kim Simpfendorfer⁶, Hongxiu Wen⁵, Joyce Hui-Yuen⁷, Boris Reizis⁸, Sohei Makita⁸ and Betsy Barnes⁵, ¹Northwell- Cohen Children's Medical Center, Elmhurst, NY, ²The Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ⁴Feinstein Institutes for Medical Science, Manhasset, ⁵Feinstein Institutes for Medical Science, Manhasset, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Northwell Health, Cohen Children's Medical Center, Great Neck, NY, ⁸New York University Grossman School of Medicine, New York, NY
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic, chronic, autoimmune disease in which over 50% of pSLE patients develop lupus nephritis (pLN). Neutrophil extracellular traps (NETs)…
Abstract Number: 1842 • ACR Convergence 2024
Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
John Goulding¹, John Reiser², Alison O'Connor¹, Bryan Hancock¹, Jonatan Tuncel¹, Brian Groff¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Allan Williams¹, Dan Lu¹, Bi-Huei Yang¹, Eigen Peralta¹, Alma Gutierrez¹, Miguel Meza¹, Betsy Rezner¹, Amanda Sims¹, Alec Witty¹, Yijia Pan¹, Mark Jelcic¹, Shohreh Sikaroodi¹, Matthew Denholtz¹, Tom Lee¹, Anil Bagri¹, Lilly Wong¹, Jode Goodridge¹ and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Fate Therapeutics Inc, San Diego, CA
Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
Abstract Number: 1979 • ACR Convergence 2024
Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease
Siddhartha Goutam¹, Arjun athreya Raghavan², Carrie Ye³, Liam O'Neil⁴ and Jeffrey Graham¹, ¹Max Rady School of Medicine, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have altered the treatment landscape within oncology, with an expanding number of indications. Patients with pre-existing autoimmune disease (PAD) have…
Abstract Number: 2079 • ACR Convergence 2024
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Silvia Grazzini¹, Angeles Galindo-Feria², Edoardo Conticini¹, Ingrid Lundberg³ and Maryam Dastmalchi⁴, ¹Università di Siena, Siena, Italy, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska University hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
Abstract Number: 2404 • ACR Convergence 2024
Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
Caroline Stone¹, Daniella Faden¹, Lillian Xie¹, Lais Lopes Almeida Gomes¹, Joshua Dan¹, Cristina Ricco¹, Ahmed Eldaboush¹ and Victoria Werth², ¹University of Pennsylvania, philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatoscopes are emerging as efficient, valuable alternatives to capillaroscopy for evaluating rheumatologic conditions. Second to systemic sclerosis, nailfold capillaroscopy abnormalities are most consistently reported…
Abstract Number: 2538 • ACR Convergence 2024
HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…
Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Monica Moreno, Shon Green, Kevin P. Nishimoto, Jackie Kennedy-Wilde, Taylor Barca, Melinda Au, Simona Costanzo, Gregory Vosganian, Benjamin Hsu, Francesco Galimi and Blake T. Aftab, Adicet Therapeutics, Inc., Redwood City, CA
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 0252 • ACR Convergence 2024
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Aurélien Chepy¹, Michaël Genin², Louis Terriou³, Cécile Chenivesse⁴, Delphine Staumont-Sallé⁵, Hélène Zéphir⁶, Peggy philippe⁷, Guillaume Lefevre⁸, Sarah Stabler⁹, Eric HACHULLA³, David Launay¹⁰ and Vincent Sobanski³, ¹Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, ²Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, ⁴Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, ⁵Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, ⁶Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, ⁸CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, ⁹CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France
Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
Abstract Number: 0317 • ACR Convergence 2024
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Pablo Moreno-Fresneda¹, Cristina Vadillo-Font², Fredeswinda Romero-Bueno³, Olga Sánchez-Pernaute⁴, Rosalía Laporta⁵, hildegarda Godoy Tundidor⁶, Belén López-Muñiz⁷, Laura Cebrián⁷, Claudia Valenzuela⁸, Irene Llorente-Cubas⁹, Jesús Loarce¹⁰, Juan Rigual¹⁰, Benjamin fernandez-Gutierrez¹¹, M Asuncion Nieto¹ and lydia Abasolo Alcazar¹², ¹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ²Hospital Clinico S Carlos, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁶Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ⁸ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ⁹Hospital Universitario de La Princesa, Madrid, Spain, ¹⁰Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ¹¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Spain
Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…

« Previous Page
1
…
6
7
8
9
10
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].